DreaMed Diabetes is a medical device and SaaS company providing personalized diabetes treatment optimization solutions. The company, established as a spin-off of the DREAM International Consortium, commercializes the insulin control technology behind Glucositter, an artificial pancreas technology that was published in the New England Journal of Medicine. DreaMed Diabetes offers a clinically proven decision-support system for insulin titration in type-1 diabetes patients. Its Advisor Pro software was created by diabetes professionals and is based on real-world experience and artificial intelligence. Using it, any healthcare professional can analyze patient data in seconds and advise on the optimal treatment plan. With frequent titration changes and online monitoring, Advisor Pro enables better patient treatment, lowering their A1C levels and risk for complications. Using the Advisor Pro, physicians and nurses can provide true patient-centered care, and everyone can receive the same high-quality treatment. DreaMed Diabetes is working on decision-support tools in the diabetes management space and received a CE Mark and FDA clearance for a decision-support system using data from CGM/SMBG and insulin pumps.